LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Home・Aandelen Lijst・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Gesloten

2.13 0.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.02

Max

2.2

Belangrijke statistieken
By Trading Economics
K/W Sectorgemiddelde	1.444 35.293
EPS	-0.43
Werknemers	8

Dividenden
By Dow Jones
Volgende Winsten	3 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4M 14M
Vorige openingsprijs	1.66
Vorige sluitingsprijs	2.13

Minerva Neurosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sep 2025, 21:59 UTC

Winsten

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sep 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

17 sep 2025, 23:39 UTC

Marktinformatie

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sep 2025, 22:19 UTC

Acquisities, Fusies, Overnames

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sep 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sep 2025, 21:00 UTC

Winsten

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

17 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sep 2025, 19:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sep 2025, 18:43 UTC

Marktinformatie

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sep 2025, 18:38 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sep 2025, 18:20 UTC

Marktinformatie

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sep 2025, 18:14 UTC

Marktinformatie

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sep 2025, 17:59 UTC

Marktinformatie

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sep 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sep 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sep 2025, 16:51 UTC

Winsten

Correct: Exor 1H Net Loss -EUR624M

17 sep 2025, 16:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 16:34 UTC

Marktinformatie

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sep 2025, 16:25 UTC

Winsten

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sep 2025, 16:23 UTC

Winsten

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Vergelijking

Prijswijziging

Minerva Neurosciences Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Minerva Neurosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Over Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.